SCHEMBL7003210

SCHEMBL7003210

CC1Oc2cc([N+](=O)[O-])ccc2NC1=S

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.48
ALDH1A1 P00352 6/20 0.48
MEN1 O00255 6/20 0.48
GAA P10253 1/20 0.46
MAPT P10636 4/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPK1 P28482 1/20 0.41
PGR P06401 3/20 0.40
CAPN9 O14815 1/20 0.40
CASP3 P42574 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PARP1 P09874 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NR3C1 P04150 1/20 0.38
AR P10275 1/20 0.38
PSMB8 P28062 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6996429 0.89 ALDH1A1 (0.40) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL8112059 0.87 KMT2A (0.47) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL5514499 0.85 KMT2A (0.56) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL7001029 0.83 KMT2A (0.55) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL10514925 0.76 ALDH1A1 (0.46) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL2100537 0.75 PARP1 (0.54) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL2101407 0.75 PARP1 (0.54) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL3590372 0.75 PARP1 (0.54) KMT2AALDH1A1MEN1GAAMAPT
SCHEMBL7971002 0.75 BRD4 (0.39) ALDH1A1GAAMAPTPGRHSD17B10
SCHEMBL6999139 0.75 AKR1B1 (0.39) KMT2AALDH1A1MEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed